Phase 2 Rare Disease Trial, Recruiting NCT06010329 Sponsor: Teligene US Condition: Rare Disease
Back to Rare Disease

Phase 2 Rare Disease Trial, Recruiting

NCT06010329
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older (male or female)
  • You have been diagnosed with advanced or spreading non-small cell lung cancer (NSCLC), confirmed by a lab test on a tissue or cell sample
  • Your tumor has been tested and found to have a specific, less common change (mutation) in a gene called EGFR
  • You have at least one area of cancer that can be measured on a scan
  • You are reasonably active and able to care for yourself, based on a standard performance scale (confirm with trial site)
  • Your doctors expect you to live for more than 3 months
  • Your blood tests show your bone marrow, liver, kidneys, and blood clotting are working well enough (confirm with trial site)
  • Other inclusion criteria may also apply — confirm with trial site

Who may not be able to join:

  • You have previously been treated with a type of drug called an EGFR TKI (a targeted therapy for EGFR mutations), depending on which group of the trial you would join
  • You have had certain cancer treatments (such as chemotherapy, radiation, or immunotherapy) too recently before joining — the exact waiting period depends on the type of treatment
  • You have taken certain medications or foods that strongly affect how the body processes drugs, within the past 2 weeks or longer (confirm with trial site)
  • You had major surgery or a serious injury within 4 weeks before joining
  • You still have significant side effects from a previous cancer treatment that have not fully resolved (except for hair loss)
  • You are unable to swallow tablets, or have a serious digestive condition that would affect how your body absorbs the study drug
  • Your cancer has spread to the brain and is currently causing active problems
  • You have an active infection that has not been brought under control
  • Other exclusion criteria may also apply — confirm with trial site

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 805-300-9373

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Teligene US
Registry
ClinicalTrials.gov
Start date
27 December 2023
Est. completion
1 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Objective Response Rate (ORR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov